Cargando…

Correction to: KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer

Detalles Bibliográficos
Autores principales:	Qian, Yingying, Chai, Shoujie, Liang, Zuyu, Wang, Yongfang, Zhou, You, Xu, Xia, Zhang, Chenchen, Zhang, Min, Si, Jingxing, Huang, Feiteng, Huang, Zhangdan, Hong, Wei, Wang, Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862796/ https://www.ncbi.nlm.nih.gov/pubmed/31739795 http://dx.doi.org/10.1186/s12943-019-1093-0

Ejemplares similares

KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer
por: Qian, YingYing, et al.
Publicado: (2014)

Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway
por: Lin, Chen, et al.
Publicado: (2016)

RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer
por: Sasaki, Hidefumi, et al.
Publicado: (2012)

KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas
por: Kim, Jeong-Oh, et al.
Publicado: (2015)

Ca(2+)/calmodulin-dependent protein kinase IIγ enhances stem-like traits and tumorigenicity of lung cancer cells
por: Chai, Shoujie, et al.
Publicado: (2015)

KIF5B-RET fusion gene and its correlation with clinicopathological and prognostic features in lung cancer: a meta-analysis
por: Cong, Xiao-Feng, et al.
Publicado: (2019)

A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions
por: Estrada-Zuniga, Cynthia M., et al.
Publicado: (2022)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

Case Report: A case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib
por: Park, Ha-Young, et al.
Publicado: (2023)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
por: Lu, Chang, et al.
Publicado: (2022)

A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring KIF5B-RET Fusion Responds to First-Line Pralsetinib Treatment: A Case Report
por: Qin, Hao, et al.
Publicado: (2023)

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
por: Ke, Jun-yi, et al.
Publicado: (2023)

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
por: Zhao, Lu, et al.
Publicado: (2022)

Use of on-therapy ctDNA monitoring in a patient with KIF5B-RET fusion positive advanced non-small cell lung cancer: a case report
por: Yeung, Vincent, et al.
Publicado: (2022)

Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report
por: Wu, Ying, et al.
Publicado: (2022)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
por: Zhang, Shannon S., et al.
Publicado: (2022)

RET fusions observed in lung and colorectal cancers are sensitive to ponatinib
por: Gozgit, Joseph M., et al.
Publicado: (2018)

RET kinase alterations in targeted cancer therapy
por: Liu, Xuan, et al.
Publicado: (2020)

Identification and characterization of RET fusions in advanced colorectal cancer
por: Le Rolle, Anne-France, et al.
Publicado: (2015)

Cystic brain metastases and RET fusion in lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
por: Santoro, Massimo, et al.
Publicado: (2020)

Expert consensus on the diagnosis and treatment of RET gene fusion non‐small cell lung cancer in China
por: Pu, Xingxiang, et al.
Publicado: (2023)

Identification of RET fusions in a Chinese multicancer retrospective analysis by next‐generation sequencing
por: Shi, Minke, et al.
Publicado: (2021)

The clinical significance of RET gene fusion among Chinese patients with lung cancer
por: Xing, Puyuan, et al.
Publicado: (2020)

Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
por: Gao, Ming, et al.
Publicado: (2023)

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer
por: Wang, Chunyue, et al.
Publicado: (2022)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
por: Huang, Qin, et al.
Publicado: (2020)

Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC
por: Kim, Young-Rae, et al.
Publicado: (2008)

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
por: Guo, Robin, et al.
Publicado: (2019)

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
por: Watanabe, Satomi, et al.
Publicado: (2021)

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report
por: Zhao, Zichen, et al.
Publicado: (2022)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
por: Osta, Badi El, et al.
Publicado: (2020)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase
por: Moccia, Marialuisa, et al.
Publicado: (2015)

Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report
por: Meng, Yan, et al.
Publicado: (2022)

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset
por: Nagasaka, Misako, et al.
Publicado: (2023)

Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples()()
por: Zhao, Chao, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ron8rf5v7oog6m6rofqiett3c9